Victrex plc 29.4% potential upside indicated by JP Morgan Cazenove

Victrex plc with ticker (LON:VCT) now has a potential upside of 29.4% according to JP Morgan Cazenove.



JP Morgan Cazenove set a target price of 1,680 GBX for the company, which when compared to the Victrex plc share price of 1,298 GBX at opening today (05/04/2024) indicates a potential upside of 29.4%. Trading has ranged between 1,152 (52 week low) and 1,716 (52 week high) with an average of 114,634 shares exchanging hands daily. The market capitalisation at the time of writing is £1,134,935,487.

Victrex plc is a United Kingdom-based holding company. The principal activity of the Company is the manufacture and sale of high-performance polymers. The Company develops solutions in polyetheretherketone (PEEK) and polyaryletherketone (PAEK) based polymers and selects semi-finished and finished parts. The Company operates through two segments: Sustainable Solutions and Medical. The Sustainable Solutions segment focuses on its energy and industrial, value-added resellers (VAR), automotive, aerospace and electronics markets. The Medical segment is focused on providing specialist solutions for medical device manufacturers. The Company’s subsidiaries include Victrex Manufacturing Limited, Invibio Limited, Invibio Knees Limited, Invibio Device Component Manufacturing Limited and Juvora Limited.